Angioimmunoblastic T-cell lymphoma primary prevention

Revision as of 21:50, 15 April 2019 by Sabawoon Mirwais (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Angioimmunoblastic T-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angioimmunoblastic T-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Biopsy

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angioimmunoblastic T-cell lymphoma primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angioimmunoblastic T-cell lymphoma primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angioimmunoblastic T-cell lymphoma primary prevention

CDC on Angioimmunoblastic T-cell lymphoma primary prevention

Angioimmunoblastic T-cell lymphoma primary prevention in the news

Blogs on Angioimmunoblastic T-cell lymphoma primary prevention

Directions to Hospitals Treating Angioimmunoblastic T-cell lymphoma

Risk calculators and risk factors for Angioimmunoblastic T-cell lymphoma primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

There are no established measures for the primary prevention of angioimmunoblastic T-cell lymphoma.

Primary Prevention

There are no established measures for the primary prevention of angioimmunoblastic T-cell lymphoma.

References


Template:WikiDoc Sources